Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy

Alexandra K. Rzepecki, Haiying Cheng, Beth N. McLellan

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

The relationship between treatment outcome and cutaneous toxicity induced by anticancer therapy has gained attention in the past decade. In this article, we have provided an overview of the 3 main classes of anticancer agents—specifically, molecularly targeted kinase inhibitors, immune checkpoint inhibitors, and cytotoxic chemotherapeutics—and described the data evaluating the association between cutaneous toxicity induced by these agents and survival benefit. Although preliminary studies are promising with regard to the potential role of cutaneous toxicities as a surrogate biomarker of efficacy of treatment, larger prospective studies are needed to confirm this relationship. Dermatologists have a unique opportunity to collaborate with oncologists in the multidisciplinary treatment paradigm by helping to identify and manage these dermatologic events in patients with cancer. A heightened awareness of these toxicities is critical, as it can potentially allow recognition of the efficacy of anticancer therapy and may influence treatment decisions and patient outcomes.

Original languageEnglish (US)
Pages (from-to)545-555
Number of pages11
JournalJournal of the American Academy of Dermatology
Volume79
Issue number3
DOIs
StatePublished - Sep 1 2018
Externally publishedYes

Fingerprint

Biomarkers
Skin
Therapeutics
Phosphotransferases
Prospective Studies
Survival
Neoplasms

Keywords

  • biomarker
  • cancer outcome
  • cutaneous adverse event
  • cutaneous toxicity
  • oncodermatology
  • prognostic marker
  • survival

ASJC Scopus subject areas

  • Dermatology

Cite this

Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy. / Rzepecki, Alexandra K.; Cheng, Haiying; McLellan, Beth N.

In: Journal of the American Academy of Dermatology, Vol. 79, No. 3, 01.09.2018, p. 545-555.

Research output: Contribution to journalReview article

@article{a3e873ccfe474cafa631f68c956cdb97,
title = "Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy",
abstract = "The relationship between treatment outcome and cutaneous toxicity induced by anticancer therapy has gained attention in the past decade. In this article, we have provided an overview of the 3 main classes of anticancer agents—specifically, molecularly targeted kinase inhibitors, immune checkpoint inhibitors, and cytotoxic chemotherapeutics—and described the data evaluating the association between cutaneous toxicity induced by these agents and survival benefit. Although preliminary studies are promising with regard to the potential role of cutaneous toxicities as a surrogate biomarker of efficacy of treatment, larger prospective studies are needed to confirm this relationship. Dermatologists have a unique opportunity to collaborate with oncologists in the multidisciplinary treatment paradigm by helping to identify and manage these dermatologic events in patients with cancer. A heightened awareness of these toxicities is critical, as it can potentially allow recognition of the efficacy of anticancer therapy and may influence treatment decisions and patient outcomes.",
keywords = "biomarker, cancer outcome, cutaneous adverse event, cutaneous toxicity, oncodermatology, prognostic marker, survival",
author = "Rzepecki, {Alexandra K.} and Haiying Cheng and McLellan, {Beth N.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.jaad.2018.04.046",
language = "English (US)",
volume = "79",
pages = "545--555",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy

AU - Rzepecki, Alexandra K.

AU - Cheng, Haiying

AU - McLellan, Beth N.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - The relationship between treatment outcome and cutaneous toxicity induced by anticancer therapy has gained attention in the past decade. In this article, we have provided an overview of the 3 main classes of anticancer agents—specifically, molecularly targeted kinase inhibitors, immune checkpoint inhibitors, and cytotoxic chemotherapeutics—and described the data evaluating the association between cutaneous toxicity induced by these agents and survival benefit. Although preliminary studies are promising with regard to the potential role of cutaneous toxicities as a surrogate biomarker of efficacy of treatment, larger prospective studies are needed to confirm this relationship. Dermatologists have a unique opportunity to collaborate with oncologists in the multidisciplinary treatment paradigm by helping to identify and manage these dermatologic events in patients with cancer. A heightened awareness of these toxicities is critical, as it can potentially allow recognition of the efficacy of anticancer therapy and may influence treatment decisions and patient outcomes.

AB - The relationship between treatment outcome and cutaneous toxicity induced by anticancer therapy has gained attention in the past decade. In this article, we have provided an overview of the 3 main classes of anticancer agents—specifically, molecularly targeted kinase inhibitors, immune checkpoint inhibitors, and cytotoxic chemotherapeutics—and described the data evaluating the association between cutaneous toxicity induced by these agents and survival benefit. Although preliminary studies are promising with regard to the potential role of cutaneous toxicities as a surrogate biomarker of efficacy of treatment, larger prospective studies are needed to confirm this relationship. Dermatologists have a unique opportunity to collaborate with oncologists in the multidisciplinary treatment paradigm by helping to identify and manage these dermatologic events in patients with cancer. A heightened awareness of these toxicities is critical, as it can potentially allow recognition of the efficacy of anticancer therapy and may influence treatment decisions and patient outcomes.

KW - biomarker

KW - cancer outcome

KW - cutaneous adverse event

KW - cutaneous toxicity

KW - oncodermatology

KW - prognostic marker

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85051365876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051365876&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2018.04.046

DO - 10.1016/j.jaad.2018.04.046

M3 - Review article

C2 - 29733938

AN - SCOPUS:85051365876

VL - 79

SP - 545

EP - 555

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 3

ER -